Drug Type Antibody drug conjugate (ADC) |
Synonyms tri-specific anti-Her1/Her3 Zybody(Zyngenia) |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | United States | 01 Nov 2025 | |
| Head and Neck Neoplasms | Preclinical | United States | 01 Nov 2025 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 01 Nov 2025 |






